This review discusses the mechanisms of ventricular remodeling and pharmacological approaches to prevent it in both animal models and human trials.
Does not alter clinical management of remodeling; leaves open optimal human pharmacological strategies.
Ventricular remodeling, recently characterized as an inhomogeneous entity, has quickly become a therapeutic target. It is assumed that prevention of ventricle remodeling would stop the progression of heart failure. In this review we discuss briefly the issue of ventricular remodeling along with underlying mechanisms leading to cardiac hypertrophy and/or dilatation. Furthermore, we discuss the pharmacologic approaches to prevent left ventricle remodeling, either in animal studies or human trials.
No takes yet. Share an insight, caveat, or question.
Tomasik et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: